Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
about
High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.Control of B lymphocyte development and functions by the mTOR signaling pathways.Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.One size doesn't fit all in Ph-like ALL.Philadelphia chromosome-like acute lymphoblastic leukemia.Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Precision medicine in pediatric oncology.Agents in Development for Childhood Acute Lymphoblastic Leukemia.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.How is the Ph-like signature being incorporated into ALL therapy?Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations.SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
P2860
Q37739018-DC7CEFF2-7C7A-426B-8252-893B27177B63Q38674507-CA9D9F45-E5C7-435C-B18B-AF6E168D90AAQ38706865-DE7D5B26-8A4D-45F2-968A-92F200B76C14Q40314122-81BE1708-56A9-48CF-ACB7-C2032FB3C90BQ41670884-1A223D0D-7B0E-4997-8178-5E56A2B2DEDFQ42330718-67F34DC9-EBF1-4989-A208-43C9156F09BFQ43431904-4E6035ED-0C05-4B24-BAAE-1E62C61578CDQ46711660-5EAB8B4C-7736-46C7-9F28-F77F0BD10C6AQ47095048-F8577CFD-E80B-49D1-8375-1D3565E0F3FAQ47203479-F138E405-7B49-4369-AA1E-9D112D6470CEQ47392557-652DCA8F-0BB3-4DF4-93BC-262019BEA747Q47837260-A7FD1192-A951-45B2-BFD0-04C1F4DEA15EQ49787386-D7105140-911D-4C0C-92D6-6FA660668851Q50098629-BEEA7E5A-9603-4E2E-965A-D041A6671DD1Q50308754-C0245540-7BF7-47DD-8F8A-7ADB82D8991DQ50799489-C7CA3974-5A80-46F0-A659-4B2EF5767C05Q54109030-1ED78FFC-3B5E-4ECE-A613-205AB732A75AQ55263249-6C036A81-84BA-4D38-A07F-E74F21E3CDCBQ55273917-F9DFEDE0-7A72-49A8-9E15-B6D4582916AB
P2860
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@en
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@nl
type
label
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@en
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@nl
prefLabel
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@en
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P1433
P1476
Potent efficacy of combined PI ...... acute lymphoblastic leukemia.
@en
P2093
Alexander E Perl
Cheryl L Willman
David T Teachey
I-Ming Chen
Martin Carroll
Mignon L Loh
Richard C Harvey
Sarah K Tasian
Stephan A Grupp
P2860
P304
P356
10.1182/BLOOD-2016-05-707653
P407
P577
2016-10-24T00:00:00Z